Effects of glucagon-like PEPTIDE-1 receptor agonists on incidence of hepatocellular carcinoma and liver decompensation in patients with diabetes: A systematic review and META-analysis

IF 4.4 3区医学 Q1 MEDICINE, GENERAL & INTERNAL

European Journal of Clinical Investigation Pub Date : 2025-02-12 DOI:10.1111/eci.70000

Andrea Pasta, Antonio Facciorusso, Maria Corina Plaz Torres, Edoardo G. Giannini, Rodolfo Sacco

引用次数: 0

Abstract

This systematic review and meta-analysis evaluated the impact of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on hepatocellular carcinoma (HCC) and liver decompensation in patients with type 2 diabetes. Analysing over 641,377 patients, GLP-1RA use was associated with a significant 58% reduction in HCC risk, particularly in patients with cirrhotis. While a trend towards reduced liver decompensation risk was observed, it was not statistically significant. These findings suggest a potential role for GLP-1RAs in HCC risk stratification and prevention strategies.

Abstract Image

查看原文本刊更多论文

胰高血糖素样肽-1受体激动剂对糖尿病患者肝细胞癌和肝脏失代偿发生率的影响：一项系统综述和meta分析

本系统综述和荟萃分析评估了胰高血糖素样肽-1受体激动剂（GLP-1RAs）对2型糖尿病患者肝细胞癌（HCC）和肝脏失代偿的影响。通过对641,377例患者的分析，GLP-1RA的使用与HCC风险显著降低58%相关，特别是在肝硬化患者中。虽然观察到肝失代偿风险降低的趋势，但没有统计学意义。这些发现提示GLP-1RAs在HCC风险分层和预防策略中的潜在作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Clinical Investigation 医学-医学：内科

CiteScore

9.50

自引率

3.60%

发文量

192

审稿时长

1 months

期刊介绍： EJCI considers any original contribution from the most sophisticated basic molecular sciences to applied clinical and translational research and evidence-based medicine across a broad range of subspecialties. The EJCI publishes reports of high-quality research that pertain to the genetic, molecular, cellular, or physiological basis of human biology and disease, as well as research that addresses prevalence, diagnosis, course, treatment, and prevention of disease. We are primarily interested in studies directly pertinent to humans, but submission of robust in vitro and animal work is also encouraged. Interdisciplinary work and research using innovative methods and combinations of laboratory, clinical, and epidemiological methodologies and techniques is of great interest to the journal. Several categories of manuscripts (for detailed description see below) are considered: editorials, original articles (also including randomized clinical trials, systematic reviews and meta-analyses), reviews (narrative reviews), opinion articles (including debates, perspectives and commentaries); and letters to the Editor.